SYNTHESIS AND USE OF NOVEL FLUORESCENT GLYCOSPHINGOLIPIDS FOR ESTIMATING BETA-GLUCOSIDASE ACTIVITY IN-VITRO IN THE ABSENCE OF DETERGENTS AND SUBTYPING GAUCHER DISEASE VARIANTS FOLLOWING ADMINISTRATION INTO INTACT-CELLS

被引:11
作者
AGMON, V
CHERBU, S
DAGAN, A
GRACE, M
GRABOWSKI, GA
GATT, S
机构
[1] HEBREW UNIV JERUSALEM,HADASSAH MED SCH,DEPT MEMBRANE BIOCHEM & NEUROCHEM,IL-91010 JERUSALEM,ISRAEL
[2] CUNY MT SINAI SCH MED,DIV MED & MOLEC GENET,NEW YORK,NY 10029
关键词
GLYCOSPHINGOLIPID; BETA-GLUCOSIDASE ACTIVITY; GAUCHER DISEASE; FIBROBLAST; (HUMAN);
D O I
10.1016/0005-2760(93)90177-B
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Two novel fluorescent glycolipids, LRO-glucosylceramide (LRO-GC) and LRO-trihexosylceramide (LRO-THC) were synthesized and utilized for estimating activities of the lysosomal, acid beta-glucosidase in cell extracts and intact skin fibroblasts, derived from normal individuals and patients with Gaucher disease subtypes. The uniqueness of the glycolipids is the fact that a fluorescent probe (lissamine rhodamine) is linked in a sulfonylamide linkage to the sphingosyl residue of the sphingolipid. Thus, the product of enzymatic hydrolysis, lissamine rhodamine sulfonylamido sphingosine (LRO-ceramide) cannot be further hydrolyzed and remains a metabolic end product. A unique property of LRO-GC as a substrate for the lysosomal, acid beta-glucosidase in vitro was the observation that enzymatic hydrolysis occurs in the absence of detergents and that hydrolytic rates are, in fact, reduced in the presence of Triton X-100 and/or sodium taurocholate. Also, both glycolipids penetrated the membrane of intact fibroblasts in the absence of serum and were hydrolyzed in lysosomes of the intact cells. The rates of intracellular hydrolysis decreased with the severity of the Gaucher disease subtypes. Using LRO-THC as substrate, the intracellular ratio of LRO-ceramide to LRO-glucosylceramide was an indicator for the specific GD-subtype.
引用
收藏
页码:72 / 79
页数:8
相关论文
共 27 条
[11]  
GRACE ME, 1990, J BIOL CHEM, V265, P6827
[12]   GAUCHER DISEASE TYPE-1 - CLONING AND CHARACTERIZATION OF A CDNA-ENCODING ACID BETA-GLUCOSIDASE FROM AN ASHKENAZI JEWISH PATIENT [J].
GRAVES, PN ;
GRABOWSKI, GA ;
EISNER, R ;
PALESE, P ;
SMITH, FI .
DNA-A JOURNAL OF MOLECULAR & CELLULAR BIOLOGY, 1988, 7 (08) :521-528
[13]  
HE GS, 1992, IN PRESS HUM MUTATIO
[14]   ARTIFICIAL SUBSTRATES IN ASSAY OF ACID GLYCOSIDASES [J].
HULTBERG, B ;
OCKERMAN, PA .
CLINICA CHIMICA ACTA, 1972, 39 (01) :49-&
[15]   HETEROGENEITY OF MUTATIONS IN THE ACID BETA-GLUCOSIDASE GENE OF GAUCHER DISEASE PATIENTS [J].
LATHAM, TE ;
THEOPHILUS, BDM ;
GRABOWSKI, GA ;
SMITH, FI .
DNA AND CELL BIOLOGY, 1991, 10 (01) :15-21
[16]  
MATTHEWS REF, 1982, 4 INT COMM TAX VIR
[17]   UPTAKE AND METABOLISM OF A FLUORESCENT SULFATIDE ANALOG IN CULTURED SKIN FIBROBLASTS [J].
MONTI, E ;
PRETI, A ;
NOVATI, A ;
ALEO, MF ;
CLEMENTE, ML ;
MARCHESINI, S .
BIOCHIMICA ET BIOPHYSICA ACTA, 1992, 1124 (01) :80-87
[18]   HUMAN ACID BETA-GLUCOSIDASE - USE OF INHIBITORS, ALTERNATIVE SUBSTRATES AND AMPHIPHILES TO INVESTIGATE THE PROPERTIES OF THE NORMAL AND GAUCHER DISEASE ACTIVE-SITES [J].
OSIECKINEWMAN, K ;
FABBRO, D ;
LEGLER, G ;
DESNICK, RJ ;
GRABOWSKI, GA .
BIOCHIMICA ET BIOPHYSICA ACTA, 1987, 915 (01) :87-100
[19]   HUMAN ACID BETA-GLUCOSIDASE - INHIBITION STUDIES USING GLUCOSE ANALOGS AND PH VARIATION TO CHARACTERIZE THE NORMAL AND GAUCHER DISEASE GLYCON BINDING-SITES [J].
OSIECKINEWMAN, K ;
LEGLER, G ;
GRACE, M ;
DINUR, T ;
GATT, S ;
DESNICK, RJ ;
GRABOWSKI, GA .
ENZYME, 1988, 40 (04) :173-188
[20]   ENZYMATIC AMPLIFICATION OF BETA-GLOBIN GENOMIC SEQUENCES AND RESTRICTION SITE ANALYSIS FOR DIAGNOSIS OF SICKLE-CELL ANEMIA [J].
SAIKI, RK ;
SCHARF, S ;
FALOONA, F ;
MULLIS, KB ;
HORN, GT ;
ERLICH, HA ;
ARNHEIM, N .
SCIENCE, 1985, 230 (4732) :1350-1354